- Home
- EYPT vs STEW Comparison
EYPT vs STEW Comparison
Compare EYPT & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | STEW |
|---|---|---|
| Founded | 1987 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | STEW |
|---|---|---|
| Price | $16.21 | $18.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 84.5K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | ★ $42,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.91 | $11.97 |
| 52 Week High | $19.11 | $14.94 |
Technical Indicators
Market Signals| Indicator | EYPT | STEW |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 56.80 |
| Support Level | $16.67 | $18.31 |
| Resistance Level | $18.20 | $18.63 |
| Average True Range (ATR) | 1.01 | 0.16 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 3.56 | 60.53 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.